David B Solit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5561227/publications.pdf

Version: 2024-02-01

335	57,974	906 116	1158 229
papers	citations	h-index	g-index

353	353	353	57988
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	7.0	28
2	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	2.5	7
3	BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences. Cancer Research, 2022, 82, 12-14.	0.9	3
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
5	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	3.0	5
6	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	27.8	44
7	The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. Clinical Cancer Research, 2022, 28, 2669-2678.	7.0	6
8	AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature Communications, 2022, 13, 2111.	12.8	10
9	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1450-1459.	2.5	10
10	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Clinical Genitourinary Cancer, 2022, 20, 431-441.	1.9	5
11	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
12	Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1010-1010.	1.6	6
13	Targeting HER2 mutationâ€“positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.. Journal of Clinical Oncology, 2022, 40, 4079-4079.	1.6	11
14	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	3.0	6
15	Overcoming barriers to tumor genomic profiling through direct patient social media outreach.. Journal of Clinical Oncology, 2022, 40, 6532-6532.	1.6	0
16	Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.. Journal of Clinical Oncology, 2022, 40, 4083-4083.	1.6	0
17	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	9.4	7
18	Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, 4110-4110.	1.6	0

#	Article	IF	Citations
19	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	7.0	4
20	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 817-825.	1.5	8
21	Lessons from the Study of Exceptional Responders. Cancer Cell, 2021, 39, 11-13.	16.8	26
22	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	7.0	15
23	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. European Urology, 2021, 79, e56-e57.	1.9	0
24	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clinical Cancer Research, 2021, 27, 2011-2022.	7.0	19
25	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
26	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	12.8	64
27	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10
28	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	4.3	52
29	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
30	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	16.3	79
31	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS ONE, 2021, 16, e0248097.	2.5	5
32	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	7.0	8
33	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
34	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-GuÃ©rin Immunotherapy in Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2021, 27, 4599-4609.	7.0	26
35	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	16.8	65
36	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68

#	Article	IF	Citations
37	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	5.9	15
38	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€“Small Cell Lung or Colorectal Cancer. JAMA Network Open, 2021, 4, e2117547.	5.9	20
39	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell, 2021, 39, 1375-1387.e6.	16.8	78
40	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
41	TNFR2/14-3-3Îµ signaling complex instructs macrophage plasticity in inflammation and autoimmunity. Journal of Clinical Investigation, 2021, 131, .	8.2	42
42	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
43	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer, 2021, 7, 1-6.	0.4	2
44	Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. Cancer Research, 2021, 81, 5161-5175.	0.9	7
45	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	7.3	73
46	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	3.0	2
47	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer, 2021, 124, 1214-1221.	6.4	14
48	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	7.0	25
49	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. American Journal of Surgical Pathology, 2021, 45, 77-92.	3.7	30
50	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	7.0	6
51	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating Î²-Catenin Signaling. Molecular Cancer Research, 2021, 19, 573-584.	3.4	10
52	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	21.4	44
53	HER2â€‰+â€‰breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications, 2021, 12, 6667.	12.8	47
54	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	12.8	15

#	Article	IF	Citations
55	Intracellular Signaling. , 2020, , 24-46.e12.		0
56	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	7.1	66
57	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	1.6	60
58	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer, 2020, 126, 4126-4135.	4.1	5
59	Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. Journal of Pathology, 2020, 250, 464-465.	4.5	8
60	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	5.0	60
61	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	13.2	45
62	The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) â‰¥10: a decision centered on empowering patients and their physicians. Annals of Oncology, 2020, 31, 1115-1118.	1.2	161
63	A phase 2 trial of buparlisib in patients with platinumâ€resistant metastatic urothelial carcinoma. Cancer, 2020, 126, 4532-4544.	4.1	14
64	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology, 2020, 159, 150-156.	1.4	43
65	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	1.9	21
66	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. Urology, 2020, 144, 111-116.	1.0	5
67	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
68	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	3.0	9
69	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	3.0	1
70	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	10.7	243
71	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2020, 26, 3230-3238.	7.0	112
72	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	12.8	31

#	Article	IF	Citations
73	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical Cancer Research, 2020, 26, 2932-2945.	7.0	35
74	Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. Clinical Chemistry, 2020, 66, 616-618.	3.2	35
75	37. Spatiotemporal patterns of metastatic spread and survival from MSK-IMPACT, a large-scale prospective clinical sequencing. Cancer Genetics, 2020, 244, 14.	0.4	0
76	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.9	18
77	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer, 2020, 126, 1995-2002.	4.1	26
78	Regorafenib in Combination with Firstâ€Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	3.7	10
79	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	9.4	83
80	Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	7.0	62
81	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
82	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	12.8	37
83	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology, 2020, 78, 671-679.	1.9	72
84	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	7.0	59
85	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	3.0	93
86	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
87	Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting. Clinical Cancer Research, 2020, 26, 1538-1540.	7.0	25
88	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	8.2	28
89	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	1.4	0
90	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer, 2019, 22, 355-362.	5.3	11

#	Article	IF	Citations
91	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	7.0	104
92	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
93	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	27.8	295
94	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
95	Frequency and outcomes of brain metastases in patients with HER2â€mutant lung cancers. Cancer, 2019, 125, 4380-4387.	4.1	51
96	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	7.0	30
97	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	5.2	31
98	Precision Oncology: Three Small Steps Forward. Cancer Cell, 2019, 35, 825-826.	16.8	11
99	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	2.8	8
100	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology, 2019, 30, 597-603.	1.2	114
101	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	4.5	37
102	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	7.0	10
103	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
104	â€œPrimaryâ€•and â€œsecondaryâ€•muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes. Translational Cancer Research, 2019, 8, S642-S644.	1.0	1
105	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. JCO Precision Oncology, 2019, 3, 1-13.	3.0	6
106	Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2019, 3, 1-9.	3.0	23
107	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research, 2019, 25, 7381-7387.	7.0	13
108	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122

#	Article	IF	Citations
109	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. American Journal of Surgical Pathology, 2019, 43, 920-927.	3.7	59
110	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	30.7	485
111	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. JCO Precision Oncology, 2019, 3, 1-9.	3.0	26
112	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	7.0	44
113	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	7.1	426
114	Regional differences in gallbladder cancer pathogenesis: Insights from a multiâ€institutional comparison of tumor mutations. Cancer, 2019, 125, 575-585.	4.1	34
115	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
116	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
117	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164
118	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	7.0	390
119	Genomic Differences Between â€œPrimaryâ€•and â€œSecondaryâ€•Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	1.9	104
120	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
121	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. European Urology Focus, 2019, 5, 365-368.	3.1	20
122	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Investigation, 2019, 129, 4276-4289.	8.2	134
123	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. Blood, 2019, 134, 2148-2148.	1.4	3
124	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery, 2018, 8, 648-661.	9.4	97
125	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 2018, 173, 515-528.e17.	28.9	540
126	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572

#	Article	IF	Citations
127	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	9.4	275
128	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
129	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	2.0	27
130	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118.	7.0	200
131	Effects of Co-occurring Genomic Alterations on Outcomes in Patients withKRAS-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323
132	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	7.0	85
133	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	12.6	834
134	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
135	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
136	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	1.6	399
137	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	1.6	381
138	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	1.6	1,109
139	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
140	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
141	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell, 2018, 34, 852-862.e4.	16.8	73
142	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
143	Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. New England Journal of Medicine, 2018, 378, 1945-1947.	27.0	56
144	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical Cancer Research, 2018, 24, 4154-4161.	7.0	348

#	Article	IF	Citations
145	Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Annals of Internal Medicine, 2018, 168, 221.	3.9	6
146	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
147	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	21.4	411
148	Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews Cancer, 2018, 18, 527-528.	28.4	34
149	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	1.5	19
150	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. Clinical Cancer Research, 2018, 24, 5815-5819.	7.0	25
151	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	7.1	139
152	Commentary on â€œDNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.â€• Urologic Oncology: Seminars and Original Investigations, 2018, 36, 345-346.	1.6	1
153	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	1.4	10
154	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. Journal of Clinical Oncology, 2018, 36, 1504-1504.	1.6	2
155	A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.. Journal of Clinical Oncology, 2018, 36, 2502-2502.	1.6	39
156	Microsatellite instability in prostate cancer and response to immune checkpoint blockade.. Journal of Clinical Oncology, 2018, 36, 5020-5020.	1.6	14
157	A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.0	268
158	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Medicine, 2017, 9, 4.	8.2	170
159	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	7.0	225
160	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2017, 77, 1035-1046.	0.9	15
161	Transcriptional Mechanisms of Resistance to Antiâ€“PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	7.0	67
162	An Acquired HER2â€ˆT798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutantâ€“Driven Breast Cancer. Cancer Discovery, 2017, 7, 575-585.	9.4	85

#	Article	IF	Citations
163	Gene Signature Associated with Upregulation of the Wnt/Î²-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. Journal of Vascular and Interventional Radiology, 2017, 28, 349-355.e1.	0.5	14
164	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
165	AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery, 2017, 7, 818-831.	9.4	1,235
166	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
167	Nextâ€generation sequencing of urine specimens: A novel platform for genomic analysis in patients with nonâ€“muscleâ€invasive urothelial carcinoma treated with bacille Calmetteâ€GuÃ©rin. Cancer Cytopathology, 2017, 125, 416-426.	2.4	26
168	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Annals of Oncology, 2017, 28, 512-518.	1.2	171
169	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
170	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Annals of Oncology, 2017, 28, 3015-3021.	1.2	79
171	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
172	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	7.0	161
173	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 2017, 548, 234-238.	27.8	394
174	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
175	Oncologist use and perception of large panel next-generation tumor sequencing. Annals of Oncology, 2017, 28, 2298-2304.	1.2	31
176	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer, 2017, 123, 568-575.	4.1	39
177	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	7.1	191
178	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19, 89.	5.0	45
179	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	1.9	263
180	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	286

#	Article	IF	Citations
181	AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	1.6	240
182	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
183	Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget, 2017, 8, 66117-66127.	1.8	80
184	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	3.0	275
185	Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response.. Journal of Clinical Oncology, 2017, 35, 4511-4511.	1.6	28
186	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 300-300.	1.6	7
187	PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget, 2017, 8, 23529-23538.	1.8	31
188	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	1.8	10
189	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
190	Reply to M.P. Decatris et al. Journal of Clinical Oncology, 2016, 34, 887-887.	1.6	1
191	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	27.0	1,205
192	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
193	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology, 2016, 70, 771-775.	1.9	69
194	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
195	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 4000-4007.	1.6	147
196	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	4.1	50
197	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling, 2016, 9, ra33.	3.6	54
198	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.4	30

#	Article	IF	Citations
199	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e81-e90.	1.9	4
200	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374.	1.5	49
201	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	7.1	270
202	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
203	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	21.4	143
204	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.4	36
205	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
206	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnology, 2016, 34, 155-163.	17.5	634
207	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	1.4	16
208	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. Journal of Clinical Oncology, 2016, 34, 4538-4538.	1.6	6
209	Tumor Genetic Screening Programs: A Call to Action. Journal of Clinical Oncology, 2015, 33, 2725-2726.	1.6	14
210	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European Urology, 2015, 67, 198-201.	1.9	122
211	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer, 2015, 121, 1195-1203.	4.1	146
212	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	3.7	57
213	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical Cancer Research, 2015, 21, 1935-1943.	7.0	124
214	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 4099-4105.	1.6	88
215	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	1.9	202
216	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	6.4	136

#	Article	IF	Citations
217	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell, 2015, 28, 370-383.	16.8	392
218	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244.	27.8	486
219	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS ONE, 2015, 10, e0126633.	2.5	41
220	Perturbation biology nominates upstreamâ€“downstream drug combinations in RAF inhibitor resistant melanoma cells. ELife, 2015, 4, .	6.0	95
221	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Blood, 2015, 126, 481-481.	1.4	0
222	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0
223	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E748-57.	7.1	90
224	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	9.4	506
225	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology, 2014, 15, 454.	8.8	296
226	Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	9.4	114
227	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. Cancer Research, 2014, 74, 2340-2350.	0.9	266
228	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	9.4	73
229	Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors. Clinical Cancer Research, 2014, 20, 3712-3720.	7.0	88
230	Towards a Unified Model of RAF Inhibitor Resistance. Cancer Discovery, 2014, 4, 27-30.	9.4	39
231	Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies. Journal of the National Cancer Institute, 2014, 106, dju214-dju214.	6.3	44
232	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 207-212.	2.3	37
233	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer, 2014, 120, 2316-2324.	4.1	170
234	Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged. Cancer Cell, 2014, 26, 603-604.	16.8	49

#	Article	IF	Citations
235	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery, 2013, 3, 294-307.	9.4	53
236	ERK Pathway Inhibitors: How Low Should We Go?. Cancer Discovery, 2013, 3, 719-721.	9.4	47
237	Tumor adaptation and resistance to RAF inhibitors. Nature Medicine, 2013, 19, 1401-1409.	30.7	512
238	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	1.6	282
239	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics, 2013, 45, 253-261.	21.4	324
240	BRAF Mutation is associated with early stage disease and improved outcome in patients with lowâ€grade serous ovarian cancer. Cancer, 2013, 119, 548-554.	4.1	169
241	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. PLoS Computational Biology, 2013, 9, e1003290.	3.2	128
242	Pilot study of 68Ga-DOTA-F(abâ€²)2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165.	1.1	68
243	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clinical Cancer Research, 2013, 19, 2257-2264.	7.0	136
244	Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells. Cancer Research, 2013, 73, 1156-1167.	0.9	83
245	Phase <scp>II</scp> study of everolimus in metastatic urothelial cancer. BJU International, 2013, 112, 462-470.	2.5	153
246	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	1.6	254
247	RAF/MEK Dependence of KRAS-Mutant Pancreatic Ductal Adenocarcinomas: Figure 1.. Cancer Discovery, 2012, 2, 666-669.	9.4	10
248	Genomic Complexity and AKT Dependence in Serous Ovarian Cancer. Cancer Discovery, 2012, 2, 56-67.	9.4	109
249	BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. Cancer Discovery, 2012, 2, 791-797.	9.4	194
250	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	27.0	222
251	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	12.6	681
252	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 101-111.	2.3	67

#	Article	IF	Citations
253	Primed for resistance. Nature, 2012, 483, 44-45.	27.8	13
254	Monitoring the Induction of Heat Shock Factor 1/Heat Shock Protein 70 Expression following 17-Allylamino-Demethoxygeldanamycin Treatment by Positron Emission Tomography and Optical Reporter Gene Imaging. Molecular Imaging, 2012, 11, 7290.2011.00028.	1.4	11
255	Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?. Clinical Cancer Research, 2012, 18, 2420-2422.	7.0	15
256	A phase 2 study of the insulinâ€like growth factorâ€1 receptor inhibitor MKâ€0646 in patients with metastatic, wellâ€differentiated neuroendocrine tumors. Cancer, 2012, 118, 4795-4800.	4.1	59
257	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
258	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487, 500-504.	27.8	1,561
259	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 1089-1097.	2.3	30
260	Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 201-205.	2.3	5
261	Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging. Molecular Imaging, 2012, 11, 67-76.	1.4	7
262	Resistance to BRAF Inhibition in Melanomas. New England Journal of Medicine, 2011, 364, 772-774.	27.0	222
263	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	21.4	270
264	Resistance to MEK Inhibitors: Should We Co-Target Upstream?. Science Signaling, 2011, 4, pe16.	3.6	110
265	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480, 387-390.	27.8	1,298
266	The â€œSWOTâ€•of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. Current Oncology Reports, 2011, 13, 479-487.	4.0	33
267	Somatic mutation of fibroblast growth factor receptorâ€3 (FGFR3) defines a distinct morphological subtype of highâ€grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	4.5	73
268	Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition. Clinical Cancer Research, 2011, 17, 122-133.	7.0	36
269	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research, 2011, 17, 5132-5139.	7.0	396
270	CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER. , 2011, , 559-615.		0

#	Article	IF	Citations
271	4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors. Cancer Cell, 2010, 18, 39-51.	16.8	360
272	How melanomas bypass new therapy. Nature, 2010, 468, 902-903.	27.8	52
273	Tracing cancer networks with phosphoproteomics. Nature Biotechnology, 2010, 28, 1028-1029.	17.5	16
274	Somatic mutations of the Parkinson's diseaseâ€“associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics, 2010, 42, 77-82.	21.4	336
275	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	1.6	129
276	Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response. Clinical Cancer Research, 2010, 16, 3329-3334.	7.0	160
277	PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Research, 2010, 70, 6804-6814.	0.9	146
278	Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244). Cancer Research, 2010, 70, 2264-2273.	0.9	222
279	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14903-14908.	7.1	417
280	The familial Parkinson Disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell Cycle, 2010, 9, 1451-1452.	2.6	32
281	Oncogenic RAF: a brief history of time. Pigment Cell and Melanoma Research, 2010, 23, 760-762.	3.3	9
282	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research, 2010, 70, 5901-5911.	0.9	245
283	^{V600E} BRAF is associated with disabled feedback inhibition of RAFâ€“MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4519-4524.	7.1	535
284	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 2009, 15, 5049-5059.	7.0	338
285	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440.	7.1	246
286	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 2436-2442.	1.6	92
287	Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1. Cancer Research, 2009, 69, 4885-4893.	0.9	488
288	Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 264-270.	1.6	55

#	Article	IF	Citations
289	The current state of preclinical prostate cancer animal models. Prostate, 2008, 68, 629-639.	2.3	121
290	Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature Biotechnology, 2008, 26, 91-100.	17.5	108
291	HGF/MET rescues Gefitinib treated non-small cell lung cancer cells carrying an activating EGFR mutation. Journal of the American College of Surgeons, 2008, 207, S100-S101.	0.5	0
292	Development and application of Hsp90 inhibitors. Drug Discovery Today, 2008, 13, 38-43.	6.4	253
293	Therapeutic strategies for inhibiting oncogenic BRAF signaling. Current Opinion in Pharmacology, 2008, 8, 419-426.	3.5	72
294	Genetic Predictors of MEK Dependence in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383.	0.9	235
295	Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma. Cancer Research, 2008, 68, 5524-5528.	0.9	206
296	SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers. Clinical Cancer Research, 2008, 14, 240-248.	7.0	175
297	BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2194-2201.	3.6	112
298	HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3499-3508.	4.1	121
299	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel. Cancer Research, 2008, 68, 589-596.	0.9	172
300	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. Clinical Cancer Research, 2008, 14, 8302-8307.	7.0	193
301	Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. Clinical Cancer Research, 2007, 13, 1775-1782.	7.0	198
302	Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2â€“Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2007, 25, 5410-5417.	1.6	333
303	3â€²-Deoxy-3â€²-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Research, 2007, 67, 11463-11469.	0.9	66
304	Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors. PLoS ONE, 2007, 2, e810.	2.5	107
305	Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 2121-2127.	7.0	14
306	A polyvalent vaccine for high-risk prostate patients: â€œare more antigens better?â€• Cancer Immunology, Immunotherapy, 2007, 56, 1921-1930.	4.2	64

#	Article	IF	Citations
307	A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2007, 59, 467-475.	2.3	52
308	Therapeutic Strategies for Targeting BRAF in Human Cancer. Reviews on Recent Clinical Trials, 2007, 2, 121-134.	0.8	40
309	mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research, 2006, 66, 1500-1508.	0.9	2,329
310	BRAF mutation predicts sensitivity to MEK inhibition. Nature, 2006, 439, 358-362.	27.8	1,264
311	Hsp90: A Novel Target for Cancer Therapy. Current Topics in Medicinal Chemistry, 2006, 6, 1205-1214.	2.1	164
312	Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors. Cancer Research, 2006, 66, 6990-6997.	0.9	76
313	Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. Journal of Nuclear Medicine, 2006, 47, 793-6.	5.0	136
314	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell, 2005, 8, 287-297.	16.8	372
315	Pilot Trial of Unlabeled and Indium-111â€“Labeled Antiâ€“Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 7454-7461.	7.0	120
316	Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel. Clinical Cancer Research, 2005, 11, 1983-1989.	7.0	128
317	Generation of DOTA-Conjugated Antibody Fragments for Radioimmunoimaging. Methods in Enzymology, 2004, 386, 262-275.	1.0	8
318	Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnology, 2004, 22, 701-706.	17.5	288
319	Hsp90: the vulnerable chaperone. Drug Discovery Today, 2004, 9, 881-888.	6.4	219
320	Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90. Chemistry and Biology, 2004, 11, 787-797.	6.0	159
321	New Efficient Synthesis of Resorcinylic Macrolides via Ynolides:â€‰ Establishment of Cycloproparadicicol as Synthetically Feasible Preclinical Anticancer Agent Based on Hsp90 as the Target. Journal of the American Chemical Society, 2004, 126, 7881-7889.	13.7	159
322	Hsp90 as a therapeutic target in prostate cancer. Seminars in Oncology, 2003, 30, 709-716.	2.2	140
323	Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer, 2003, 98, 1842-1848.	4.1	35
324	Title is missing!. Angewandte Chemie, 2003, 115, 1318-1322.	2.0	13

#	Article	IF	Citations
325	Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12337-12342.	7.1	84
326	Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90. Current Cancer Drug Targets, 2003, 3, 371-376.	1.6	106
327	Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Research, 2003, 63, 2139-44.	0.9	227
328	Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clinical Cancer Research, 2003, 9, 4340-6.	7.0	214
329	Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Research, 2003, 63, 8393-9.	0.9	51
330	Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function. Journal of Biological Chemistry, 2002, 277, 39858-39866.	3.4	539
331	Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 2002, 21, 1159-1166.	5.9	251
332	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical Cancer Research, 2002, 8, 986-93.	7.0	357
333	HER-Kinase-Directed Therapy of Prostate Cancer. Prostate Journal, 2001, 3, 53-58.	0.2	2
334	BRAF mutations in human cancer: biologic and therapeutic implications. , 0, , 272-277.		0
335	Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. , 0, .		2